Screener
uniQure QURE Q2 2026 earnings
Reported July 29, 2026 · Before market open
Revenue$5.8MBeat by $391.9K
EPS-$1.22Miss by $0.40
Revenue estimate$5.4M
EPS estimate-$0.82
“Following a productive Type B meeting with the FDA, we remain on track to submit our BLA for AMT-130 in the third quarter — a milestone that reflects years of rigorous science, disciplined execution, and an unwavering commitment to the patients and families living with this devastating disease. With four-year data expected in September and the U.K. regulatory activities progressing as planned, we enter the second half of 2026 with real momentum and a clear line of sight to potentially bringing this therapy to the people who need it.”
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$6.2M
EPS estimate-$0.84
Valuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did uniQure report Q2 2026 earnings?
- uniQure (QURE) reported Q2 2026 earnings on July 29, 2026 before market open.
- What were uniQure's Q2 2026 revenue and EPS?
- uniQure reported revenue of $5.8M and eps of $-1.22 for Q2 2026.
- Did uniQure beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $5.4M by $391.9K. EPS missed the consensus estimate of $-0.82 by $0.40.
- How did uniQure's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 11.0% from $5.3M a year earlier and eps declined 76.8% from $-0.69.
- Where can I find uniQure's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-087808) and the 10-Q periodic report (0001104659-26-087815) directly on SEC EDGAR. The filing index links above go to sec.gov.
